Lumida
/FULC
⌘K
Fulcrum Therapeutics Inc

Fulcrum Therapeutics Inc

FULC
$3.84USD+0.52%+0.02 today

MARKET CAP

293.0M

P/E (TTM)

FWD P/E

DAY RANGE

$4 – $4

52W RANGE

$3
$16

AI Summary

Stalk
TrimMedium

FULC remains in Stage 4 decline with a clear lower-high/lower-low sequence under declining EMAs and price confined below the 9EMA/21EMA region. A terminal Double Bottom suggests exhaustion, but without confirmed EMA repair or a higher high, bearish control persists. The recommended posture is to trim into any rally toward the overhead EMA zone. A sustained close and follow-through above the 21EMA would invalidate this bearish bias.

  • Stock at $3.74 vs. $8.20 target implies 119% upside potential
  • High 13F hedge fund ownership suggests strong institutional interest
  • Pociredir termination undermines credibility and removes key revenue driver
Full analysis →
Insider Trades6 trades
DateSideTickerInsiderRoleSharesPriceMkt Cap52W High52W LowValue% ChgRuleAI View
Dec 15, 2025SellFULCCurtis Gale OltmansChief Legal Officer3,452$12.92$293.0M-75.60%+35.69%$44.6K-25.19%10b5-1Trim
May 8, 2025SellFULCGreg TourangeauPrincipal Accounting Officer498$5.06$293.0M-75.60%+35.69%$2.5K-3.42%Trim
Jul 3, 2024BuyFULCAlex Sapir150,000$3.27$293.0M-75.60%+35.69%$490.5K+6.46%Trim
May 7, 2024SellFULCGreg TourangeauPrincipal Accounting Officer236$7.76$293.0M-75.60%+35.69%$1.8K-2.00%Trim
Mar 8, 2024SellFULCGreg TourangeauVice President, Finance4,884$11.72$293.0M-75.60%+35.69%$57.2K-29.26%Trim
Mar 4, 2024BuyFULCAlex Sapir43,360$11.35$293.0M-75.60%+35.69%$492.0KTrim